Editorial

Restaging Laparotomy and Ovarian Cancer

Authors: JACK A. LUCAS MD, WILLIAM S. ROBERTS MD, JOHN J. KAVANAGH MD, and, DENIS CAVANAGH MD

Abstract

ABSTRACT: We retrospectively reviewed the records of 41 patients who had restaging laparotomy after initial surgery and chemotherapy for ovarian cancer. In 37 of them, the cancer was epithelial. Stage and amount of residual disease after initial cytoreductive surgery correlated with laparotomy outcome. There were no operative deaths, and perioperative morbidity was relatively minor. Of the 25 patients with residual disease after initial cytoreductive surgery ten had a complete response, eight had a partial response, two had stable disease, and five had progression. Three patients (11.5%) had recurrent disease after a negative restaging laparotomy. We discuss salvage therapy and the value of restaging laparotomy in ovarian cancer.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References